Rekombinanter CCR4 (Mogamulizumab Biosimilar) Antikörper

Produktnummer ABIN7795114

Der Humanized Monoklonal anti-CCR4 (Mogamulizumab Biosimilar) Antikörper (ABIN7795114) detektiert spezifisch CCR4 (Mogamulizumab Biosimilar) in FACS und in vivo. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für Rekombinanter CCR4 (Mogamulizumab Biosimilar) Antikörper (ABIN7795114)

Target: CCR4 (Mogamulizumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Humanized

Klonalität: Monoklonal

Konjugat: Dieser CCR4 (Mogamulizumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-CCR4 (Mogamulizumab Biosimilar) Antikörper

Expressionssystem: Mammalian cells

Verwendungszweck: Mogamulizumab Biosimilar, CCR4 Monoclonal Antibody

Produktmerkmale: Mogamulizumab Biosimilar uses the same protein sequences as the therapeutic antibody mogamulizumab. Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous, these cancers typically affect the skin, causing various types of skin lesions. Mogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Mogamulizumab selectively binds to and inhibits the activity of CCR4, which may block CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, as well as chemokine-mediated angiogenesis. Additionally, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and certain types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells. In addition to directly targeting malignant T cells expressing CCR4, mogamulizumab depletes Treg cells, an important therapeutic target in many human cancers because of their role in suppressing host antitumor immunity.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human CCR4

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Details zu CCR4 (Mogamulizumab Biosimilar)

Target: CCR4 (Mogamulizumab Biosimilar)

Andere Bezeichnung: Mogamulizumab Biosimilar

Substanzklasse: Biosimilar